Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Continuous glucose monitoring enhanced by geriatric care principles reduced the duration of hypoglycemia without worsening ...

TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, ...

Trinity Biotech today announced that it completed the first pre-pivotal clinical trial in Europe for its next-generation CGM ...

A device used by diabetics is now over-the-counter, making it easier for people to get. The device could be so helpful, so diabetics could get off their medications. The device is called a CGM or ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

Continuous Glucose Monitoring Devices Market to reach a value of US$ 12.51 Bn by 2031 at a CAGR of 9.9% between 2024 and 2031 BURLINGAME, CA, UNITED STATES, October 15, 2024 /EINPresswire / -- A ...

In recent years, digital health has become a new development trend in the global health and medical industry. By using ...

Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...

Trinity Biotech’s Chief Technology Officer, Dr Gary Keating, added, “Our next phase of refinements, guided by this study’s positive results, will be tested in a second European pre-pivotal trial, ...